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BACKGROUND: Colorectal cancer is common in England and, with long-term survival relatively poor, improving outcomes is a priority.
A major initiative to reduce mortality from the disease has been the introduction of the National Health Service (NHS) Bowel
Cancer Screening Programme (BCSP). Combining data from the BCSP with that in the National Cancer Data Repository (NCDR)
allows all tumours diagnosed in England to be categorised according to their involvement with the BCSP. This study sought to
quantify the characteristics of the tumours diagnosed within and outside the BCSP and investigate its impact on outcomes.
METHODS: Linkage of the NCDR and BCSP data allowed all tumours diagnosed between July 2006 and December 2008 to be
categorised into four groups; screen-detected tumours, screening-interval tumours, tumours diagnosed in non-participating invitees
and tumours diagnosed in those never invited to participate. The characteristics, management and outcome of tumours in each
category were compared.
RESULTS: In all, 76 943 individuals were diagnosed with their first primary colorectal cancer during the study period. Of these 2213
(2.9%) were screen-detected, 623 (0.8%) were screening-interval cancers, 1760 (2.3%) were diagnosed in individuals in non-
participating invitees and 72 437 (94.1%) were diagnosed in individuals not invited to participate in the programme due to its ongoing
roll-out over the time period studied. Screen-detected tumours were identified at earlier Dukes’ stages, were more likely to be
managed with curative intent and had significantly better outcomes than tumours in other categories.
CONCLUSION: Screen-detected cancers had a significantly better prognosis than other tumours and this would suggest that the BCSP
should reduce mortality from colorectal cancer in England.
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Colorectal cancer is the third most common cancer in the United
Kingdom and the second leading cause of cancer death (Cancer
Research UK, 2011). Long-term outcomes from the disease in the
United Kingdom are poor with international survival comparisons
showing that survival is significantly lower than in many
comparable countries (Coleman et al, 2011; Morris et al, 2011).
Redressing this survival deficit is a priority for the National Health
Service (NHS) (Department of Health, 2007).
Numerous studies have now demonstrated that regular screen-
ing reduces the risk of dying from colorectal cancer (Mandel et al,
1993; Kronborg et al, 1996; Hardcastle et al, 1996; Jorgensen et al,
2002; Faivre et al, 2004) so, to improve colorectal cancer outcomes,
the NHS implemented a national Bowel Cancer Screening
Programme (BCSP). The scheme began in July 2006 and rolled
out incrementally across the country achieving national coverage
in 2010. Initially, it offered screening to all men and women
resident in England and registered with a general practitioner
between the ages of 60 and 69 years but from 2010 it began to be
extended to include everyone up to the age of 74 years. Older
people may also self-refer into the programme. The screening
process has been described in detail elsewhere (Logan et al, 2011)
but, in brief, eligible individuals are automatically sent an
invitation to participate from their regional screening hub and,
unless they indicate otherwise, sent a faecal occult blood test
(FOBt) screening kit. The kit is completed by the participant and
returned by post to the relevant hub. Those who test positive are
then offered a colonoscopy or further investigations at their local
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screening centre to determine if cancer or adenomas are present. If
so they are then referred to their local multi-disciplinary colorectal
cancer team for appropriate treatment for the disease or, for
adenomas, entered into a surveillance programme. Those who test
negative are invited to be screened again after 2 years. Evidence
from the first prevalent round of screening by the NHS BCSP has
demonstrated an overall participation rate of 49.6% of men and
54.4% of women although involvement varied by both age and
level of deprivation too (Logan et al, 2011; von Wagner et al, 2011).
The NHS BCSP actively audits its performance and has collected
comprehensive data about all individuals eligible for the scheme in
a single national system. The data gathered cover all aspects of the
screening process as well as detailed pathological information
about any adenomas and tumours detected. This system allows the
characteristics and patterns of identification of screen-detected
tumours to be quantified. To compare screen-detected tumours to
those identified symptomatically, however, information is needed
about all the other colorectal tumours identified in the country.
Such information is available from the National Cancer Data
Repository (NCDR; National Cancer Intelligence Network, 2011)
(that has recently been developed by the National Cancer
Intelligence Network (NCIN) and the United Kingdom Association
of Cancer Registries (UKACR)) which contains information about
the characteristics and management of all colorectal tumours
diagnosed in England. Linking these two data sets enables screen-
detected tumours to be identified within a population-based data
set of all other colorectal tumours. It also enables all tumours to be
categorised into groups based on their involvement or otherwise in
the screening programme. For example, it is possible to identify
those that are screen-detected, those that occur in the interval
between a negative screening test and the date the next test is due,
those that occur in invited non-participants of the scheme and
those that occur in individuals never invited to participate in the
programme. The aim of this study was to exploit this linked data
set to examine the characteristics of the tumours in each group and
to investigate any variation between the tumours in each category
and their subsequent management.
MATERIALS AND METHODS
All patients diagnosed with their first primary colorectal cancer
(International Classification of Disease Version 10, World Health
Organisation, 2004; (ICD10) codes C18-C20) diagnosed in England
between 4 July 2006 and the 31 December 2008 were extracted from
the NCDR. This time period was selected as the NHS BCSP began
in July 2006 and, at the time of analysis, the NCDR was complete
for cancer registrations up until the end of 2008. As such, this time
period represented the maximum available cross-over between the
two data sets.
Information taken from the cancer registry data within the
NCDR included age, sex, site of tumour, Dukes’ stage of disease at
diagnosis (the only currently nationally available staging variable)
and, where relevant, date of death. Management information for
each tumour was also extracted from the Hospital Episode
Statistics (HES) data within the resource. A primary procedure
was sought for every individual who could be identified in both the
registry and HES data sets. Initially, major resections (as defined
by the OPCS Classification of Interventions and Procedures
version 4 (NHS Connecting for Health, 2009a, b) (OPCS4) codes
in Appendix 1) were identified for all linked patients within 12
months of the date of diagnosis of the tumour. If a patient
underwent two or more major colorectal resections during
different episodes of treatment, then the first operation was used.
If a patient underwent two or more procedures during the same
episode, then the most radical or extensive procedure was used.
If no major resection could be identified for an individual, then
their hospital episodes were searched again for other surgical
interventions in the order of minor resection and then palliative
procedures such as bypass, formation of a stoma or insertion of
a stent (defined using the OPCS4 (NHS Connecting for Health,
2009a, b) codes in Appendix 1). If no primary procedure could be
identified but an individual linked to HES, then individuals were
allocated to the ‘no surgical treatment in the NHS category’. No
management information was available for some individuals as
they could not be identified in HES (because, for instance, they
were treated privately or died without receiving any treatment) and
were included in a separate category.
This extract of NCDR data was then linked at a patient level to
the NHS BCSP data set using all or combinations of the identifiers
of NHS number, date of birth, postcode and sex. Tumours were
then categorised into four groups (Table 1).
The first category of tumours was called ‘screen-detected’ and
included all cancers that were identified as a result of investiga-
tions undertaken within the screening programme and that were
identified as such in the BCSP data set. This group included both
individuals invited to participate as they were within the eligible
age range as well those who self-referred into the scheme. The next
category was called ‘interval’ tumours. These were defined as all
tumours diagnosed in the interval between the closure of a
previous negative screening episode up to the date the next
screening test was due or, if a person was screened at 69 years and
so was no longer in the eligible age range for the scheme, up to 2
years after their last negative screening episode. The third category
Table 1 Tumour categories
Tumour
category Tumour category definition Subcategory Subcategory definition
1. Screen detected All tumours diagnosed as a result of investigations undertaken within the screening programme
2. Interval All tumours diagnosed in the interval between the closure of a previous negative screening episode and the due date of the next appropriate
screening test
3. Non-participants All tumours diagnosed in individuals who had refrained from any involvement in the screening programme
Under age All tumours identified in individuals who (at diagnosis) were too young to
be eligible to participate in screening programme
4. Never invited All tumours diagnosed in individuals never invited
to participate in the screening programme over
the course of the study
Screening
age range
All tumours identified in individuals within the screening age range but who
due to the gradual roll-out of the screening programme over the study
period were not invited
Over age All tumours identified in individuals who (at diagnosis) were too old to be
eligible to be invited automatically to participate in screening programme
Tumour categories in the English NHS BCSP
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included all those tumours diagnosed in those invited to
participate in the scheme but who declined. The final category
was called ‘never invited’ and included all those diagnosed in
individuals who were never invited to participate in the screening
programme over the course of the study period. This group has
been further broken down into different age groups according to
potential eligibility for the scheme. These groups include those
who (over the time period of this study) were not invited due to
being too young (under the age of 60 years) or too old (over the
age of 69 years) to be eligible for the scheme. The remainder were
in the screening age range of 60–69 years but were not invited to
participate over the course of this study due to the ongoing roll-out
of the programme over the time period examined.
Comparisons were then made between tumours in each group
in terms of sex, site of the tumour, Dukes’ stage at diagnosis,
treatment, 30-day post procedural mortality and 1-year survival.
Tumours in the appendix, caecum, ascending colon, hepatic
flexure and transverse colon (ICD10 C180-C184) were considered
to be right-sided whereas those at the splenic flexure and in
the descending colon, sigmoid colon and rectosigmoid junction
were considered to be left-sided tumours (ICD10 C185-C19).
Tumours overlapping two sites in the colon (C188) or with no
site specified (C189) were included in a category called colon
not otherwise specified. In all, 30-day post-primary procedure
mortality was defined as the percentage of patients dead within 30
days of their primary procedure. The statistical significance of any
differences in these characteristics across groups was assessed
using the w2 test. Survival time was calculated from the date of
diagnosis to the date of death or when censored (31 December
2009). The statistical significance of differences in survival time
was assessed using the log-rank test.
RESULTS
Over the study period 4596 tumours were diagnosed in individuals
both eligible for and invited to participate in the screening
programme. Of these 2123 (48.2%) were screen-detected, 623
(13.6%) were interval cancers and the remainder 1760 (38.3%)
occurred in individuals who were invited to participate but
refused. Of the screen-detected tumours 53 (2.5%) occurred in
individuals who were outside the eligible age range of the scheme
but had self referred into it. A further 72 437 tumours were
diagnosed in the population across all age ranges. Of these 15 265
occurred in individuals in the screening age range but who had not
been invited to participate due to the ongoing roll-out of the
programme. Over the study period the total number of individuals
diagnosed with a colorectal tumour was 76 943.
There were significant differences in the characteristics of the
individuals and tumours between the groups (Table 2) and, due to
the number of individuals included in the study, the majority
of the differences between groups are statistically significant. For
instance, the male/female distribution varied greatly between tumour
categories and a significantly higher proportion of screen-detected
tumours were diagnosed in males than in females (69.2% vs 61.0%
in the never-invited group of screening age range Po0.001).
Table 2 Characteristics of the study population
Screen
detected Interval
Non-
participant
Never
invited (o60)
Never
invited (60-69)
Never
invited (469) Total
Characteristic n % n % n % n % n % n % n %
Sex
Male 1470 69.2 350 56.2 1100 62.5 6821 55.9 9307 61.0 23 184 51.6 42 232 54.9
Female 653 30.8 273 43.8 660 37.5 5387 44.1 5958 39.0 21 780 48.4 34 711 45.1
IMD income category
Most affluent 457 21.5 116 18.6 267 15.2 2612 21.4 3305 21.7 8981 20.0 15 738 20.5
2 451 21.2 134 21.5 331 18.8 2460 20.2 3461 22.7 9741 21.7 16 578 21.5
3 473 22.3 147 23.6 339 19.3 2391 19.6 3149 20.6 9814 21.8 16 313 21.2
4 422 19.9 106 17.0 350 19.9 2323 19.0 2760 18.1 8758 19.5 14 719 19.1
Most deprived 292 13.8 103 16.5 420 23.9 2092 17.1 2313 15.2 6920 15.4 12 140 15.8
Unknown 28 1.3 17 2.7 53 3.0 330 2.7 277 1.8 750 1.7 1455 1.9
Tumour site
Right colon 416 19.6 223 35.8 518 29.4 3021 24.7 4036 26.4 14 722 32.7 22 936 29.8
Left colon 1047 49.3 196 31.5 562 31.9 4054 33.2 5304 34.7 13989 31.1 25 152 32.7
Colon NOS 79 3.7 48 7.7 139 7.9 881 7.2 1119 7.3 4787 10.6 7053 9.2
Rectum 581 27.4 156 25.0 541 30.7 4252 34.8 4806 31.5 11 466 25.5 21 802 28.3
Primary procedure
Major resection 1698 80.0 472 75.8 1226 69.7 8492 69.6 10818 70.9 26 039 57.9 48 745 63.4
Minor resection 198 9.3 20 3.2 60 3.4 375 3.1 483 3.2 1768 3.9 2904 3.8
Palliative procedure 17 0.8 23 3.7 104 5.9 628 5.1 767 5.0 2494 5.5 4033 5.2
No in-patient NHS procedure 114 5.4 85 13.6 290 16.5 1950 16.0 2484 16.3 11 358 25.3 16 281 21.2
No information 96 4.5 23 3.7 80 4.5 763 6.3 713 4.7 3305 7.4 4980 6.5
Duke’s stage at diagnosis
A 614 28.9 74 11.9 192 10.9 1237 10.1 1667 10.9 3990 8.9 7774 10.1
B 517 24.4 137 22.0 385 21.9 2662 21.8 3889 25.5 11 261 25.0 18 851 24.5
C 497 23.4 196 31.5 514 29.2 3499 28.7 4187 27.4 9851 21.9 18 744 24.4
D 121 5.7 130 20.9 315 17.9 2304 18.9 2621 17.2 6858 15.3 12 349 16.0
Unknown 374 17.6 86 13.8 354 20.1 2506 20.5 2901 19.0 13 004 28.9 19 225 25.0
Total 2123 623 1760 12 208 15 265 44 964 76 943
Abbreviations: IMD¼ Index of Multiple Deprivation; NHS¼National Health Service; NOS¼Not Otherwise Specified.
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There were also differences in the proportion of individuals in
each category in terms of the level of socio-economic deprivation
of their area of residence. A significantly higher proportion of
tumours among non-participants (23.9%) were diagnosed in
individuals who resided in the most deprived areas of the country
while across the other tumour categories the proportion in this
group was relatively constant ranging between 13.8% and 17.1%
(Po0.001 across all groups).
There were also differences between the locations of tumours
within the bowel between the groups (Figure 1). A greater
proportion of screen-detected tumours compared with those
arising in the never-invited group of identical age to the screening
programme (77.1% vs 66.2% Po0.01) were located within the left
side of the colon or the rectum compared with the right side of the
bowel (figures ranged between 53.7% and 68.0% in the other
tumour categories).
Tumours diagnosed within the screening programme were also
significantly more likely to be of an earlier stage than those
diagnosed in the never-invited group of screening age (Figure 2,
Po0.01). After excluding tumours for which no staging informa-
tion was available 35.1% of screen-detected tumours were Dukes’ A
at diagnosis compared with between 12.5% and 13.8% across the
other tumour categories. Likewise only 6.9% of screen-detected
tumours had metastatic disease at diagnosis (or Dukes’ D disease)
compared with between 21.2% and 24.2% in the other categories.
There were also major differences in the treatments used to
manage tumours in each of the categories (Figure 3). A signi-
ficantly greater proportion of screen-detected tumours received
both major resections (80.0%) and minor resections (where
comparable figures were 70.9% and 3.2%, respectively, Po0.01).
The proportion of cases for which no NHS surgical procedure
could be identified was also significantly smaller for screen-
detected cancers at 5.4%. In other categories, the proportion
ranged from 13.6% to 26.3%. Among those who underwent
some form of surgical procedure there was also a significant
difference across groups in the 30-day post procedure mortality
(Table 3). There was a 1.1% 30-day mortality rate among
individuals who had a major resection for screen-detected tumours
compared with a rate of 2.8% in the comparable age range never-
invited group (Po0.01). There was no significant difference in the
30-day post operative mortality rate for major resections between
individuals with tumours in the interval category compared with
those in the never-invited screening age range category (2.3% vs
2.8%, P¼ 0.273).
Figure 4 and Table 4 demonstrate that there were also longer
term survival differences between each of the tumour categories
and, again, screen-detected tumours had the best prognosis.
One-year survival in the screen-detected category was 95.9%
(95% confidence interval (CI) 94.9–96.6%) compared with 79.6%
(95% CI 79.0–80.3%) in the never-invited group of screen age
(Po0.01). Across the other groups the same figures ranged from
63.5% (95% CI 63.0–63.9%) to 83.9% (95% CI 83.3–84.6%)
(Po0.001). It is also of note that patients with tumours in the
interval category had 1-year survival comparable to that of those
in the never-invited screening age range category (78.4% (95% CI
75.0–81.5%) vs 79.6% (95% CI 79.0–80.3%), respectively, P¼ 0.548).
DISCUSSION
This study has enabled tumours identified by the NHS BCSP to be
identified within a population-based data set of all other colorectal
tumours diagnosed in England. It has also enabled the character-
istics of tumours to be compared across groups depending on the
extent of involvement with the BCSP. This has shown that screen-
detected tumours have different characteristics to those detected
symptomatically being found more commonly in males than in
females and are more likely to be found in the left side of the
bowel. The study has also shown they have a significantly better
prognosis than non-screen-detected tumours presenting at an
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Figure 1 Distribution of tumours by their location in the bowel across
the tumour categories.
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Figure 2 Distribution of tumours by stage at diagnosis across the
tumour categories (staged cases only).
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Figure 3 The distribution of primary procedures used to treat the
tumours in each category.
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earlier stage of disease and being more likely to be managed
electively and with curative intent. They are also associated with
both a lower 30-day post procedural mortality and improved
1-year survival.
These findings are all consistent with other studies. Several other
studies have shown that a higher proportion of screen-detected
tumours are identified in males as opposed to females. This is a
particularly striking and counterintuitive finding as evidence
indicates that females are significantly more likely to participate
in screening than males (Logan et al, 2011; von Wagner et al,
2011). While the incidence and prevalence of colorectal cancer
is higher in males than in females, which may partly explain
this phenomenon (Regula et al, 2006; Brenner et al, 2007) the
proportion of males in the screen-detected group was significantly
greater than in both the interval cancer and never-invited
screening age range group and this would suggest there are fewer
women in the screen-detected group than would be anticipated
based on sex-specific incidence patterns alone. Other studies have
observed similar trends with, for example, a higher proportion of
screen-detected cancers being identified in men as opposed to
women in the Scottish BCSP(Steele et al, 2011). There is growing
evidence to indicate this phenomenon is explained by the fact that
there are major sex differences in the performance of FOBt as the
tests have a much higher sensitivity in males rather than in females
(UK Colorectal Cancer Screening Pilot Group, 2004; Malila et al,
2008; Brenner et al, 2010). This evidence in combination with the
knowledge that there are other gender differences in presentation
of colorectal cancer relating to age (Brenner et al, 2007) and
tumour site (Steele et al, 2011) should inform future efforts to
maximise the efficacy of BCSPs.
Increasing deprivation has been shown to be negatively
associated with participation in the bowel cancer screening
(Weller et al, 2007; von Wagner et al, 2009; Moss et al, 2011).
This may partly explain the observation that a much higher
proportion of tumours among non-participants of the BCSP
occurred in those residing in the most deprived areas of the
country. Interventions to increase participation rates in socio-
economically deprived areas are, therefore, important.
Differences in the site of tumours within the bowel were
observed across the different tumour categories in the study with
screen-detected tumours having a significant higher proportion of
left-sided tumours. This trend has also been seen in other studies
(Steele et al, 2011) and may be explained by FOBt being less
effective at detecting right-sided tumours due to digestive transit.
The test works by identifying haemoglobin released from bleeding
tumours. Blood released from tumours in the right of the colon has
to travel along a greater length of the bowel than that from tumours in
the left of the colon and this may lead to a greater chance of the
haemoglobin being degraded as it passes through the bowel. Degraded
haemoglobin will not react with the FOBt and so, potentially, lead
to more false negative results for right-sided tumours. Again, this
information should help inform future design of the BCSPs.
This study also demonstrated that a larger proportion of screen-
detected tumours are identified at an early stage than those
detected symptomatically. This trend has also been seen in many
other screening studies and programmes and is part of the
mechanism by which screening improves outcomes for the disease
(Mandel et al, 1993; Kronborg et al, 1996; Hardcastle et al, 1996;
Lindhom et al, 2008; Steele et al, 2009; Paimela et al, 2010; Steele
et al, 2011). Other studies have also observed, however, a lower
proportion of Dukes A tumours in prevalent screening cycles than
incident screening cycles (Steele et al, 2010a, b; Moss et al, 2011).
This study is based on the initial roll-out of the NHS BCSP and, for
the majority involved, these data will relate to their initial
‘prevalent’ screening cycle. In future, therefore, it is possible the
stage profile of screen-detected tumours may improve still further.
Unfortunately, this study is limited in determining the full impact
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Table 4 Crude 1-year survival
Tumour category
Percentage
1-year survival
95% Confidence
intervals
Screen detected 95.9 94.9–96.6
Interval 78.4 75.0–81.5
Non-participant 76.8 76.8–74.7
Never invited (o60) 83.9 83.3–84.6
Never invited (60–69) 79.6 79.0–80.3
Never invited (469) 63.5 63.0–63.9
Table 3 Thirty-day post procedure mortality following surgical treatments used to manage tumours in each of the tumour categories
Major resection Minor resections Palliative procedures
Deaths within
30 days
Deaths within
30 days
Deaths within
30 days
Tumour category Total procedures n % Total procedures n % Total procedures n %
Screen detected 1698 18 1.1 198 0 0.0 17 0 0.0
Interval 472 11 2.3 20 0 0.0 23 3 13.0
Non-participant 1226 46 3.8 60 0 0.0 104 14 13.5
Never invited (o60) 8492 128 1.5 375 5 1.3 628 69 11.0
Never invited (60–69) 10 818 307 2.8 483 13 2.7 767 119 15.5
Never invited (469) 26 039 2090 8.0 1768 48 2.7 2494 503 20.2
Total 48 745 2600 5.3 2904 66 2.3 4033 708 17.6
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of stage by the screening programme as it was not possible to
ascertain the stage of every tumour in the cohort and, although the
trend for the screening programme to identify tumours at an early
stage was strong, it has not been conclusively proven due to
relatively large amounts of missing staging data. The lack of these
data are due to the fact that the study is based on the routine
cancer registry data available in the NCDR and, previously, these
organisation have struggled to capture this data item for all cases
of cancer. Significant efforts are being made by registries, however,
to increase the ascertainment of staging data and in future it is
anticipated this variable will be much better populated so allowing
for the trends observed in this study to be confirmed.
These analyses have also demonstrated very different surgical
management patterns across the different tumour groups. Almost
90% of individuals with screen-detected tumours received a
resection for their disease, which is much higher than any other
group. This will be linked to the fact that those who participate in
screening appear to be healthier than those who do not (von
Wagner et al, 2009). Screen-detected tumours are also being
identified at an early stage and, hence, are much more likely to be
amenable to radical treatment. Finally, the 30-day post procedural
mortality associated with these treatments was significantly lower
than in other tumour categories, which is a positive finding given
the relatively high post-operative mortality rates seen in England
(Morris et al, 2011). Other studies have observed similar effects
(Goodyear et al, 2008; Scholefield et al, 2011; Suttie et al, 2011) and
while this may well be due to patients who participate in the
programme being of better health than their non-participating
counterparts it could also relate to the earlier stage tumours
detected in greater proportion by the BCSP carrying less risk than
the later stage tumours diagnosed outside the programme.
Finally, this study also provides evidence from a population-
based setting to suggest that the outcomes from colorectal cancer
can be improved by the introduction of a screening programme.
Unfortunately, the data available only allow variation in survival to
be quantified and this outcome measure may be problematic due
to ‘lead time bias’ (i.e., the screening programme simply identifies
tumours earlier so individuals appear to survive longer simply
because they have been diagnosed earlier). To definitively prove a
benefit to the BCSP trends in mortality would need to be assessed
instead of survival as was done in the relevant randomised trials
that originally investigated the effectiveness of such screening
programmes (Hardcastle et al, 1996; Hewitson et al, 2008;
Scholefield et al, 2011). Unfortunately though, the mortality data
that would be required to undertake such analyses are not
currently available and so this study has been restricted to survival
analyses. In addition, due to the limited follow-up information
available for the cohort only 1-year survival has been assessed.
Efforts are being made, however, to acquire the mortality data that
would be required to assess in full the impact of the BCSP.
In addition, due to the limited follow-up information available
only 1-year survival has been assessed but as the programme
continues the impact on long-term survival will be quantifiable by
these data sets. Again, differences in case mix between the groups
cannot be entirely dismissed as potentially accounting for the
survival differences observed but the effects are large and it would
seem unlikely that could explain in full the variation seen.
Another benefit to the linkage of the NCDR and NHS BCSP data
sets is that it enables the number and characteristics of interval
tumours to be quantified. This is important as, although some
tumours may legitimately develop in their entirety over the course
of a screening interval, the majority are likely to have already
existed at screening but were simply not detected by the screening
test. As such, the interval cancer rate in a screening population
could be used as a performance indicator of the programme. It is
encouraging to note, therefore, that the frequency of occurrence of
interval cancers compares favourably with other screening trials
and programmes. In addition, the management and prognosis of
these tumours was not significantly different to those detected in
individuals within the screening age range that had not been invited
to participate over the time period of this study. This indicates that
the BCSP is performing as would anticipated based on evidence
from randomised trials (Hardcastle et al, 1996). More mature data
with longer follow-up time and, hence, a greater number of
complete screening intervals will be required from the NHS BCSP,
however, before the interval cancer rate can be fully quantified.
During the time period the data in this study relate to the NHS
BCSP as it was being rolled out across the country. The NHS BCSP
did not attain national coverage until 2010 and, as such, the figures
reported in this study represent preliminary findings of the scheme
relating, in the main, to the initial or ‘prevalent’ screening cycle
only. As the BCSP becomes more established a much larger
population of individuals will have the opportunity to participate
in it. In future, therefore, there will be sufficient numbers to divide
the tumours groups into further subcategories to provide more
informative analyses. For example, the screen-detected category
could be subdivided depending on whether the tumour was
diagnosed from an initial FOBt or as part of resulting surveillance
due to the identification of adenomas. Likewise, the interval
tumour category could be further subdivided into three sub-
categories: those who were identified with a cancer following the
return of a negative FOBt kit, those who were diagnosed with a
cancer following a positive FOBt kit but negative colonoscopy and
those who had a cancer diagnosed following a negative surveillance
test. The final category of non-participants could also be further
subdivided into three groups: those who do not participate at all,
those who begin the screening process but drop out before a
conclusive outcome is determined and those who participate in a
full cycle of screening but chose not to participate in any
subsequent screening rounds. Very small numbers of individuals
fall into these subgroups currently and this has prevented
meaningful comparative analyses. As the NHS BCSP becomes
more established, however, the numbers will grow so enabling
robust analyses of the different subgroups. Patient level linkage of
the NHS BCSP data set with the planned new national cancer
registration system will ensure such data become routinely
available in a more timely manner. Such information has the
potential to optimise NHS bowel cancer screening services.
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APPENDIX 1
Table A1: OPCS4 codes used to define primary procedures
Procedure
type
OP-CS4
code OPCS4 code description
Major
resection
H01 Emergency excision of appendix
H02 Other excision of appendix
H04 Total excision of colon and rectum
H05 Total excision of colon
H06 Extended excision of right hemicolon
H07 Other excision of right hemicolon
H08 Excision of transverse colon
H09 Excision of left hemicolon
H10 Excision of sigmoid colon
H11 Other excision of colon
H12 Extirpation of lesion of colon
H29 Subtotal excision of colon
H33 Excision of rectum
H341 Open excision of lesion of rectum
X14 Pelvic exenteration
Minor
excision
H201 Fibreoptic endoscopic snare resection of lesion of
colon
H202 Fibreoptic endoscopic cauterisation of lesion of colon
H205 Fibreoptic endoscopic submucosal resection of lesion
of colon
H206 Fibreoptic endoscopic resection of lesion of colon
not elsewhere classified
H208 Endoscopic extirpation of lesion of colon other specified
H209 Endoscopic extirpation of lesion of colon unspecified
H231 Endoscopic snare resection of lesion of lower bowel
using fibreoptic sigmoidoscope
H232 Endoscopic cauterisation of lesion of lower bowel
using fibreoptic sigmoidoscope
H235 Endoscopic submucosal resection of lesion of lower
bowel using fibreoptic sigmoidoscope
H236 Endoscopic resection of lesion of lower bowel using
fibreoptic sigmoidoscope
H238 Endoscopic extirpation of lesion of lower bowel
using fibreoptic sigmoidoscope other specified
H239 Endoscopic extirpation of lesion of lower bowel
using fibreoptic sigmoidoscope unspecified
(Continued )
Procedure
type
OP-CS4
code OPCS4 code description
H261 Endoscopic snare resection of lesion of sigmoid
colon using rigid sigmoidoscope
H262 Endoscopic cauterisation of lesion of sigmoid colon
using rigid sigmoidoscope
H266 Endoscopic submucosal resection of lesion of
sigmoid colon using rigid sigmoidoscope
H267 Endoscopic resection of lesion of sigmoid colon
using rigid sigmoidoscope not elsewhere classified
H268 Endoscopic extirpation of lesion of sigmoid colon
using rigid sigmoidoscope other specified
H269 Endoscopic extirpation of lesion of sigmoid colon
using rigid sigmoidoscope unspecified
H401 Trans-sphincteric excision of mucosa of rectum
H402 Trans-sphincteric excision of lesion of rectum
H408 Operations on rectum through anal sphincter other
specified
H409 Operations on rectum through anal sphincter
unspecified
H412 Peranal excision of lesion of rectum
Palliative
procedures
H13 Bypass of colon
G74 Creation of artificial opening into ileum
H141 Tube caecostomy
H151 Loop colostomy
H152 End colostomy
H214 Fibreoptic endoscopic insertion of expanding metal
stent into colon
H243 Endoscopic insertion of tubal prosthesis into lower
bowel using fibreoptic sigmoidoscope
H244 Endoscopic insertion of expanding metal stent into
lower bowel using fibreoptic sigmoidoscope
H273 Endoscopic insertion of tubal prosthesis into sigmoid
colon using rigid sigmoidoscope
H274 Endoscopic insertion of expanding metal stent into
sigmoid colon using rigid sigmoidoscope
H314 Image guided insertion of colorectal stent
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